ABSTRACT
Moringa oleifera Lam. (Moringaceae) is a medicinally important plant, used as traditional medicine all over the world particularly in South Asia and India. Hydroalcoholic (50% v/v) root extract of M. oleifera (150 mg/kg, p.o.) with piperine (2.5 mg/kg, p.o), or curcumin (5.0 mg/kg, p.o.) was administered daily for 1 week in Female Wistar albino rats against beryllium toxicity (1.0 mg/kg, i.p. daily for 5 weeks). Beryllium altered hepatorenal function and enhanced the leakage of AST, ALT, and LDH, depleted SALP activity, and increased the level of urea, uric acid, creatinine, triglyceride and total cholesterol in the blood. Beryllium altered tissue biochemical parameters by a decrease in SDH, ALPase, ATPase activities, and increased ACPase activity, depleted hemoglobin and ALAD activity with an increase in ALAS activity and serum bilirubin. A significant amount of beryllium deposited in the liver, kidney, spleen, and bones. M. oleifera with curcumin showed better antitoxic potential by reversal of hepatorenal function towards normal and restored the activity of SDH, ALPase, ATPase, ACPase, and hemoglobin level normal. M. oleifera with curcumin effectively mobilized beryllium from the body and restored ultrastructure of liver and kidney. It was concluded that curcumin enhances the antitoxic potential of M. oleifera root extract and reduces beryllium body burden in rats.
ABSTRACT
India has over a century old tradition of development and production of vaccines. The Government rightly adopted self-sufficiency in vaccine production and self-reliance in vaccine technology as its policy objectives in 1986. However, in the absence of a full-fledged vaccine policy, there have been concerns related to demand and supply, manufacture vs. import, role of public and private sectors, choice of vaccines, new and combination vaccines, universal vs. selective vaccination, routine immunization vs. special drives, cost-benefit aspects, regulatory issues, logistics etc. The need for a comprehensive and evidence based vaccine policy that enables informed decisions on all these aspects from the public health point of view brought together doctors, scientists, policy analysts, lawyers and civil society representatives to formulate this policy paper for the consideration of the Government. This paper evolved out of the first ever ICMR-NISTADS national brainstorming workshop on vaccine policy held during 4-5 June, 2009 in New Delhi, and subsequent discussions over email for several weeks, before being adopted unanimously in the present form.